12
II. Research and Development (R&D)
The Company has two R&D units, namely Chemistry Research & Development (CR&D) and
Pharmaceutical Research & Development (PR&D). Both are approved by Department of Science
and Industrial Research, Government of India.
Chemistry Research & Development (CR&D), Thane
During 2012, Chemistry R&D provided synthesis services to Primary Shared Service, Global
Manufacturing & Supply, GSK UK. The work involved synthesis of impurities generated during the
production of certain compounds. The results of this synthesis would serve as reference standards
for mapping of impurity profiles during manufacturing.
A. Pharmaceutical Research and Development (PR&D), Nashik
Pharmaceutical R&D started using TRA (Technical risk assessment) & software aided
DoE (Design of Experiments) for developing and optimizing the manufacturing processes.
The department undertook a number of improvement initiatives, new product introductions
and new source evaluations and qualifications. PR&D also utilized the trained resources on
in-house manufacturing process improvements as well as supported new product launches
through collaborative work with various business partners.
With the increase in the number of diabetic’s patients, PR&D has initiated a project on
substituting the sugar with artificial sweeteners to significantly reduce the calorie content
of the formulations and simplify the processes used for manufacturing Liquid Oral products.
The elimination of the use of sugar will also indirectly support in reducing the carbon
footprint.
PR&D worked with Global serialization experts, various suppliers & internal stakeholders for
successful implementation of cost effective tactical solution of “Barcoding & Serialization”
for Export & Government supplies on secondary level packs. The department also worked
on commercial implementation of SMS Technology (mass encryption technology) as an anti-
counterfeit measure for Eltroxin 25 & 50 µg Tablets.
PR&D also initiated the development to support emerging markets by developing Branded
Generics products involving different internal stakeholders.
The Company continues to be privileged to have access to various research databases used
worldwide and to latest technologies developed by GlaxoSmithKline Group.
Important milestones achieved by PR&D:
•
Roll out of Technical Risk Assessment (TRA) concept to the existing products.
•
Implementation of Product performance dashboard (PPD) for major products at Nashik.
•
Developmental trials initiated for sugar substitute project.
•
PR&D supported dual sourcing strategy for raw materials and finished products to create the
flexibility and increase capacity to ensure security of supply.
•
Implementation of tactical solution of ‘Barcoding & Serialization’ for secondary packs for
institutional supplies and export orders.
•
The department successfully implemented new sources of APIs and excipients which has
resulted improvement in security of supply and in cost savings.
•
DoE implemented in few products to ensure process / formula optimisation.
•
Improved technical understanding of Albendazole LF tablets manufactured for WHO donation
programme.
Future Plans:
•
Special focus on the speedy implementation of the project to substitute the sugar with artificial
sweeteners to significantly reduce the calorie content of the formulations and simplify the
processes used for manufacturing of all Liquid Oral products in a phased manner is being
planned.
•
The department is planning to implement SMS Technology (mass encryption technology) for
major products like Augmentin on commercial scale as an anti counterfeit measure.
1...,6,7,8,9,10,11,12,13,14,15 17,18,19,20,21,22,23,24,25,26,...102